Advertisement
Advertisement
BTAI
BioXcel Therapeutics, Inc. Common Stock
0.90
USDSponsored
+0.07
+8.61%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.91
0.00
+0.37%
BTAI Earnings Reports
Positive Surprise Ratio
BTAI beat 16 of 33 last estimates.
48%
Next Report
Tomorrow
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$261.80K
/-$0.52
Implied change from Q1 26 (Revenue/ EPS)
+27.09%
/-3.70%
Implied change from Q2 25 (Revenue/ EPS)
+118.17%
/-78.78%
BioXcel Therapeutics, Inc. Common Stock earnings per share and revenue
On May 15, 2026, BTAI reported earnings of -0.54 USD per share (EPS) for Q1 26, beating the estimate of -0.84 USD, resulting in a 35.72% surprise. Revenue reached 206.00 thousand, compared to an expected 356.24 thousand, with a -42.17% difference. The market reacted with a -5.79% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.52 USD, with revenue projected to reach 261.80 thousand USD, implying an decrease of -3.70% EPS, and increase of 27.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
FAQ
What were BioXcel Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, BioXcel Therapeutics, Inc. Common Stock reported EPS of -$0.54, beating estimates by 35.72%, and revenue of $206.00K, -42.17% below expectations.
How did the market react to BioXcel Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -5.79%, changed from $1.21 before the earnings release to $1.14 the day after.
When is BioXcel Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for BioXcel Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, BioXcel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of $261.80K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement